Table 1 Segmental CpG methylation analysis of the CST6 promoter and proximal exon 1 among CST6-postive and CST6-negative breast cancer cell lines

Cell line	CpGs 1–55 ^a control	CpGs 10–55 ^b control	CpGs 10–55 ^b , 5-aza treatment	CpGs 10–55 ^b , 5-aza withdrawal	CpGs 1–23 ^c control	CpGs 24–55 ^d control	CpGs 1–31 ^e control
CST6-positive
BT-20	1%	1%	—	—	3%	0%	2%
MCF12A	16%	18%	—	—	19%	14%	15%
SK-BR-3	45%	50%	—	—	16%	67%	19%
CST6-negative
MDA-MB-435S	98%	99%	42%	40%	96%	99%	97%
MDA-MB-453	98%	97%	64%	41%	99%	97%	97%
MCF-7	89%	90%	33%	64%	90%	89%	83%
Hs578T	78%	86%	1%	73%	72%	80%	72%
MDA-MB-436	72%	76%	26%	75%	65%	77%	66%
CST6-positive	21±13	23±14	—	—	13±5	27±20	12±5
CST6-negative	87±5	90±4	33±10	59±8	84±7	88±4	83±6
t-test	P=0.0227^f	P=0.0349	P=0.0033^g	NS^h	P<0.0001^f	NS^f	P<0.0001^f

^aCpG dinucleotides from a segment of the promoter region and exon 1 (+242 to −228).
^bCpG dinucleotides from a segment of the proximal promoter region and exon 1 (+118 to −228). The values indicated under 5-aza treatment are from cell lines at the conclusion of a 3-week treatment period. The values indicated under 5-aza withdrawal are from cell lines that had recovered from 5-aza treatment for 5 weeks.
^cCPG dinucleotides from the proximal promoter region (0 to −228).
^dCpG dinucleotides from exon 1 (0 to +242).
^eCpG dinucleotides from the proximal promoter region and 8 CpGs from exon 1 (+50 to −228).
^fP-values provided reflect a statistical comparison of average TMI values corresponding to CST6-positive (n=3) and CST6-negative (n=5) cell lines for the designated gene segments.
^gP-value for the comparison of average TMI values corresponding to control and 5-aza-treated CST6-negative cell lines for the designated gene segment.
^hP-value for the comparison of average TMI values corresponding to 5-aza-treated CST6-negative cell lines and the same cell lines after 5-aza withdrawal.

Search